Is Halozyme Therapeutics, Inc. (HALO) a Buy, Sell, or Hold?
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$75.05 USD
-$1.06 (-1.39%)
- Volume
- 1.78M
- Average Volume
- 1.78M
- Market Capitalization
- $8.9B
- P/E Ratio
- 25.70
- Dividend Yield
- 0.00%
- Price Target
- $91.50
- Year High
- $82.26
- Year Low
- $55.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Helen I. Torley |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HALO |
| CUSIP | 40637H109 |
| CIK | 0001159036 |
| Web | https://www.halozyme.com |
| Phone | 858 794 8889 |
| Currency | USD |
| Employees | 423 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 9.76 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.76 |
| Quick Ratio | 2.33 |
| Cash Ratio | 0.85 |
Sales & Book Value
| Annual Sales | $1.4B |
| Price / Sales | 5.90 |
| Cash Flow | 5.65 |
| Price / Cash Flow | 13.33 |
| Price / Book | 40.37 |
Price Target and Rating
| Average Stock Price Forecast | $91.50 |
| High Stock Price Forecast | $95.00 |
| Low Stock Price Forecast | $75.00 |
| Forecast Upside/Downside | -17.98% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 27 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.56 |
| Trailing P/E Ratio | 25.70 |
| PEG Ratio | -1.06 |
| P/E Growth | -1.06 |
| Net Income | $316.89M |
| Net Margin | 23.13% |
| Pretax Margin | 33.37% |
| Return on Equity | 126.27% |
| Return on Assets | 13.05% |
Financials Score
| AltmanZ Score | 3.83 |
| Piotroski Score | 6.00 |
| Working Capital | 639.83M |
| Total Assets | 2.67B |
| Ebit | 522.48M |
| Market Cap | 9.08B |
| Total Liabilities | 2.45B |
Poll Results
About Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It als ... o plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Time to Buy Wide Moat & HALO ETFs?
2026-07-10 12:00:20
Wall Street is caught in the midst of shifting geopolitical stances of the United States and Iran, chances of higher global inflation, weak U.S. jobs data, the possibility of stagflation in the U.S. economy, and the Fed's likely dilemma in fixing the monetary policy amid a weakening labor market and accelerating inflation. Also, the occasional selloffs in the red-hot artificial intelligence (AI) space have been a steady concern.
Halozyme Appoints David Ramsay as President Drug Delivery
2026-06-30 16:02:00
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr.
2026-06-15 06:00:00
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026. "Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
2026-06-10 12:31:07
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Anti-AI Investing: The HALO Moat Goes Off The Rails
2026-06-09 08:02:18
North American railroads like UNP, NSC, CSX, CNI, and CP exhibit HALO traits: irreplaceable heavy assets, low obsolescence, and durable cash flows. Current railroad valuations are rich, with multiples well above historical averages, suggesting limited near-term upside for new investors. Greenbrier offers a contrarian opportunity: trading below normal multiples, with a $2.1B backlog and 2.9% yield despite near-term headwinds.
Sky Harbour: The Ultimate HALO Investment Taking Flight
2026-06-07 08:00:00
Sky Harbour is building a national network of private aviation campuses on some of America's most irreplaceable airport real estate. The company's business model fits squarely within my HALO framework: Heavy Assets, Low Obsolescence. Airport land is among the most supply-constrained infrastructure assets in the United States.
Anti-AI Investing: The HALO Moat
2026-05-31 08:00:00
I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookfield Infrastructure, Prologis, Rexford Industrial, Lineage, Americold, VICI Properties, and Lamar Advertising. AMT, COLD, and VICI currently offer attractive entry points based on discounted multiples, robust dividend yields, and resilient, monopoly-like asset bases.
Implied Volatility Surging for Halozyme Therapeutics Stock Options
2026-05-26 10:31:22
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Frequently Asked Questions
-
What is the current Halozyme Therapeutics, Inc. (HALO) stock price?
-
Halozyme Therapeutics, Inc.(NASDAQ:HALO) stock price is $75.05 in the last trading session. During the trading session, HALO stock reached the peak price of $82.26 while $55.64 was the lowest point it dropped to. The percentage change in HALO stock occurred in the recent session was --1.39% while the dollar amount for the price change in HALO stock was -$-1.06.
-
HALO's industry and sector of operation?
-
The NASDAQ listed HALO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HALO?
-
Darren Snellgrove | Senior Vice President & Chief Financial Officer
David A. Ramsay | President of Drug Delivery
Mark Snyder | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Rhys de Callier | Chief Strategy Officer
Charles Theuer | Chief Medical Officer -
How many employees does HALO have?
-
Number of HALO employees currently stands at 423. HALO operates from 11388 Sorrento Valley Road, San Diego, CA 92121, US.
-
Link for HALO official website?
-
Official Website of HALO is: https://www.halozyme.com
-
How do I contact HALO?
-
HALO could be contacted at phone #858 794 8889 and can also be accessed through its website. HALO operates from 11388 Sorrento Valley Road, San Diego, CA 92121, US.
-
How many shares of HALO are traded daily?
-
The average number of HALO shares traded daily for last 3 months was 1.78M.
-
What is the market cap of HALO currently?
-
The market value of HALO currently stands at $8.9B with its latest stock price at $75.05